Odds Are Stacked Against Matrixx In Bid To Rescind Zicam Warning Letter
This article was originally published in The Tan Sheet
Executive Summary
Matrixx Initiatives faces long odds against convincing FDA to withdraw a warning letter concerning the firm's Zicam intranasal products, food and drug lawyers say after the firm's request was rejected a second time
You may also be interested in...
Matrixx Touts Survey Showing Pharmacists Support Zinc Remedies
Matrixx Initiatives furthers its strategy to restore consumer trust in its troubled Zicam brand with a survey showing most pharmacists recommend zinc-based remedies for a cold.
Matrixx Touts Survey Showing Pharmacists Support Zinc Remedies
Matrixx Initiatives furthers its strategy to restore consumer trust in its troubled Zicam brand with a survey showing most pharmacists recommend zinc-based remedies for a cold.
Matrixx Touts Survey Showing Pharmacists Support Zinc Remedies
Matrixx Initiatives furthers its strategy to restore consumer trust in its troubled Zicam brand with a survey showing most pharmacists recommend zinc-based remedies for a cold.